synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
California, Illinois, and New York passed the first mandatory minimum sentences for drug offenses; Congress followed with the Boggs Act of 1951, creating the first federal mandatory minimums for drugs. The act unified penalties for the Narcotic Drugs Import and Export Act and the Marihuana Tax Act, effectively criminalizing cannabis. Anslinger testified in favor of the inclusion of cannabis, describing a "stepping-stone" path leading from cannabis to harder drugs and crime. First-offense possession of cannabis carried a 2–10-year minimum and a fine of up to $20,000. This marked a change in Congress's approach to mandatory minimums, increasing their number, severity, and the crimes they covered. According to the United States Sentencing Commission, reporting in 2012: "Before 1951, mandatory minimum penalties typically punished offenses concerning treason, murder, piracy, rape, slave trafficking, internal revenue collection, and counterfeiting. Today, the majority of convictions under statutes carrying mandatory minimum penalties relate to controlled substances, firearms, identity theft, and child sex offenses.". In 1961, the Single Convention on Narcotic Drugs became the first of three UN treaties that together form the legal framework for international drug control, and require that domestic drug laws in member countries comply with the conventions. The Single Convention unified existing international drug agreements, and limited possession and use of opiates, cannabis and cocaine to "medicinal and scientific purposes", prohibiting recreational use.
== Methodology == Operando spectroscopy is a class of methodology, rather than a specific spectroscopic technique such as FTIR or NMR. Operando spectroscopy is a logical technological progress in situ studies. Catalyst scientists would ideally like to have a "motion picture" of each catalytic cycle, whereby the precise bond-making or bond-breaking events taking place at the active site are known; this would allow a visual model of the mechanism to be constructed. The ultimate goal is to determine the structure-activity relationship of the substrate-catalyst species of the same reaction. Having two experiments—the performing of a reaction plus the real-time spectral acquisition of the reaction mixture—on a single reaction facilitates a direct link between the structures of the catalyst and intermediates, and of the catalytic activity/selectivity. Although monitoring a catalytic process in situ can provide information relevant to catalytic function, it is difficult to establish a perfect correlation because of the current physical limitations of in situ reactor cells. Complications arise, for example, for gas phase reactions which require large void volumes, which make it difficult to homogenize heat and mass within the cell. The crux of a successful operando methodology, therefore, is related to the disparity between laboratory setups and industrial setups, i.e., the limitations of properly simulating the catalytic system as it proceeds in industry.
== Scope of Services == Girteka specializes in temperature-controlled and high-value cargo transportation across the continent, delivering a wide range of goods, including fresh, chilled, frozen, and processed foods. Focusing on the following operational segments within road transportation:
Sources: en.wikipedia.org
In Islam, embalming of the dead is not practiced, except in cases of necessity, such as when a body is being transported internationally and the law requires it to be embalmed. Muslims bury their deceased without delay (preferably within 24 hours), to allow the soul to transition to the afterlife as soon as possible. Buddhists generally do not favor embalming, but it is not strictly prohibited in most Buddhist traditions. The practice of embalming varies among different Buddhist schools and cultures. In Theravada Buddhism, embalming is allowed but not considered essential. However, in Tibetan Buddhism, embalming is typically discouraged and should not take place. The increasingly global nature of communities and far longer delays between death and final disposition caused by modern requirements and often distant families mean that embalming is frequently required either by law or common sense due to issues of transportation and holding requirement. Thus most religious authorities relent to its necessity in specific circumstances
The term diabetes is derived from the Ionic for 'siphon', meaning "to pass or run through". It reflects the dominant notion at the time that fluids consumed by the diabetic patient passed through the body unchanged, as if flowing through a tube or siphon. A number of conflicting accounts exist as to the first use of this term, placing the originator as either Apollonius of Memphis (fl. 3rd century BC), Demetrius of Apamea (fl. 100 BC), or Aretaeus of Cappadocia (fl. early 2nd century AD). In-depth probes of Greek etymology agree that the term came from Demetrius of Apamea, C. L. Gemmill (1972) states:Caelius Aurelianus prepared a Latin version of the works of Soranus. In the index of the Drabkin edition there is a subject heading "Diabetes," but on examination of the text this section could not be found (footnote 3, p. 776) except for a short paragraph. In this paragraph Caelius quotes Apollonius of Memphis as separating two forms of dropsy, one marked by retention of fluid and the other by the inability to retain fluid; the patient discharges whatever he drinks as if it were passed through a pipe. Apollonius lived in the second half of the third century B.C. Caelius Aurelianus continues by stating that Demetrius of Apamea distinguishes this disease from dropsy in which any fluid that is drunk is discharged as urine. Demetrius calls this condition diabetes. The time of Demetrius of Apamea is given as the first century B.C. None of his works have come down to us; we have only quotations in later authors.
=== Iodine deficiency === Among humans with dietary iodine deficiency, the thyroid will not be able to make thyroid hormones. The lack of thyroid hormones will lead to decreased negative feedback on the pituitary gland, leading to increased production of thyroid-stimulating hormone, which causes the thyroid to enlarge in a medical condition called endemic colloid goitre. This has the effect of increasing the thyroid's ability to trap more iodide, compensating for the iodine deficiency and allowing it to produce adequate amounts of thyroid hormone.
Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis; moderate-to-severe asthma; chronic rhinosinusitis with nasal polyps; eosinophilic esophagitis; prurigo nodularis; and chronic obstructive pulmonary disease. It has been shown to be effective at treating aspirin-exacerbated respiratory disease (AERD), a typically difficult to treat condition where aspirin intolerant patients have both chronic rhinosinusitis with nasal polyps and asthma.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.